Nutex Health (NUTX) Financials

$163.73 +3.78 (+2.36%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$163.40 -0.33 (-0.20%)

As of 04:56 AM Eastern

Annual Income Statements for Nutex Health

This table shows Nutex Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	52	-46	-425
Consolidated Net Income / (Loss)	95	-43	-433
Net Income / (Loss) Continuing Operations	95	-43	-433
Total Pre-Tax Income	110	-48	-420
Total Operating Income	131	-32	-407
Total Gross Profit	196	35	15
Total Revenue	480	248	219
Operating Revenue	480	248	219
Total Cost of Revenue	133	123	124
Operating Cost of Revenue	133	123	124
Total Operating Expenses	217	157	502
Selling, General & Admin Expense	174	106	87
Depreciation Expense	19	18	13
Other Operating Expenses / (Income)	17	3.05	0.19
Impairment Charge	7.08	30	398
Restructuring Charge	0.00	0.04	3.89
Total Other Income / (Expense), net	-21	-17	-13
Interest Expense	20	16	12
Other Income / (Expense), net	-0.94	-0.40	-0.56
Income Tax Expense	14	-5.07	13
Net Income / (Loss) Attributable to Noncontrolling Interest	43	2.36	-7.96
Basic Earnings per Share	$10.25	($10.39)	($100.36)
Weighted Average Basic Shares Outstanding	5.53M	745.43M	650.93M
Diluted Earnings per Share	$9.71	($10.39)	($100.36)
Weighted Average Diluted Shares Outstanding	5.53M	745.43M	650.93M
Weighted Average Basic & Diluted Shares Outstanding	5.53M	745.43M	650.93M

This table shows Nutex Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	62	-8.79	-0.36	-0.36	-32	-5.54	-3.48	-5.15	-15	-412
Consolidated Net Income / (Loss)	100	-7.17	3.01	-0.54	-28	-4.52	-4.27	-6.92	-11	-423
Net Income / (Loss) Continuing Operations	100	-7.17	3.01	-0.54	-28	-4.52	-4.27	-6.92	-11	-423
Total Pre-Tax Income	109	-2.58	3.90	-0.15	-31	-4.87	-5.08	-7.83	-8.85	-431
Total Operating Income	114	9.66	5.30	1.45	-26	-0.82	-0.36	-4.45	-5.78	-429
Total Gross Profit	142	22	23	10	13	7.07	9.65	4.85	-3.32	-24
Total Revenue	258	79	76	67	70	63	59	56	54	28
Operating Revenue	258	79	76	67	70	63	59	56	54	28
Total Cost of Revenue	35	34	32	32	32	32	28	30	61	32
Operating Cost of Revenue	35	34	32	32	32	32	28	30	61	32
Total Operating Expenses	109	35	39	34	64	31	31	31	-1.67	426
Selling, General & Admin Expense	89	28	28	29	28	26	27	25	21	23
Depreciation Expense	5.28	4.97	4.53	4.19	4.68	4.75	4.17	3.99	3.27	4.33
Other Operating Expenses / (Income)	15	1.96	-0.06	0.05	0.64	0.05	0.25	2.12	-26	0.08
Total Other Income / (Expense), net	-5.63	-12	-1.39	-1.60	-4.57	-4.04	-4.72	-3.39	-3.07	-2.77
Interest Expense	5.05	5.38	5.05	4.44	4.24	4.10	4.84	3.14	2.86	3.40
Other Income / (Expense), net	-0.58	-6.86	3.66	2.84	-0.33	0.05	0.12	-0.25	-0.21	0.63
Income Tax Expense	8.61	4.58	0.89	0.39	-3.00	-0.34	-0.82	-0.91	1.81	-8.54
Net Income / (Loss) Attributable to Noncontrolling Interest	38	1.62	3.37	-0.18	3.91	1.02	-0.79	-1.77	4.09	-11
Basic Earnings per Share	$11.16	($1.72)	($0.07)	($0.01)	($0.04)	($1.25)	($0.79)	($0.12)	($0.02)	($0.62)
Weighted Average Basic Shares Outstanding	5.53M	5.44M	5.07M	49.72M	745.43M	670.78M	661.90M	656.56M	650.93M	649.77M
Diluted Earnings per Share	$11.16	($1.72)	($0.07)	($0.01)	($0.04)	($1.25)	($0.79)	($0.12)	($0.02)	($0.62)
Weighted Average Diluted Shares Outstanding	5.53M	5.44M	5.07M	49.72M	745.43M	670.78M	661.90M	656.56M	650.93M	649.77M
Basic & Diluted Earnings per Share	$11.16	-	-	-	($0.04)	-	-	-	($0.02)	-
Weighted Average Basic & Diluted Shares Outstanding	5.53M	5.44M	5.07M	49.72M	745.43M	670.78M	661.90M	656.56M	650.93M	649.77M
Cash Dividends to Common per Share	$0.50	-	-	-	-	-	-	-	-	-

This table details how cash moves in and out of Nutex Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	22	-12	-1.86
Net Cash From Operating Activities	23	1.26	51
Net Cash From Continuing Operating Activities	23	1.71	51
Net Income / (Loss) Continuing Operations	95	-43	-433
Consolidated Net Income / (Loss)	95	-43	-433
Depreciation Expense	19	18	13
Non-Cash Adjustments To Reconcile Net Income	74	35	401
Changes in Operating Assets and Liabilities, net	-165	-7.37	69
Net Cash From Investing Activities	-2.67	-11	-4.34
Net Cash From Continuing Investing Activities	-2.67	-11	-4.34
Purchase of Property, Plant & Equipment	-2.30	-9.50	-15
Acquisitions	0.00	-0.70	13
Other Investing Activities, net	-0.36	-1.04	-2.42
Net Cash From Financing Activities	1.09	-2.27	-48
Net Cash From Continuing Financing Activities	1.09	-2.27	-48
Repayment of Debt	-17	-22	-9.03
Payment of Dividends	-6.44	-5.21	-51
Issuance of Debt	9.28	24	3.44
Issuance of Common Equity	9.20	0.00	0.00
Other Financing Activities, net	5.73	0.30	8.69

This table details how cash moves in and out of Nutex Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-3.33	6.10	11	8.00	-4.82	-5.93	-0.08	-1.42	-2.37	-11
Net Cash From Operating Activities	0.05	6.79	13	3.05	-1.78	1.97	0.01	1.05	4.51	-7.30
Net Cash From Continuing Operating Activities	0.05	6.79	13	3.05	-1.32	1.97	0.01	1.05	4.51	-7.30
Net Income / (Loss) Continuing Operations	100	-7.17	3.01	-0.54	-28	-4.52	-4.27	-6.92	-11	-423
Consolidated Net Income / (Loss)	100	-7.17	3.01	-0.54	-28	-4.52	-4.27	-6.92	-11	-423
Depreciation Expense	5.28	4.97	4.53	4.19	4.68	4.75	4.17	3.99	3.27	4.33
Non-Cash Adjustments To Reconcile Net Income	63	9.28	4.11	-2.29	31	0.38	1.22	2.00	0.89	399
Changes in Operating Assets and Liabilities, net	-168	-0.29	1.61	1.70	-9.61	1.37	-1.11	1.97	11	13
Net Cash From Investing Activities	-0.40	-0.27	-1.27	-0.73	0.87	-3.62	-3.07	-5.42	7.88	-5.89
Net Cash From Continuing Investing Activities	-0.40	-0.27	-1.27	-0.73	0.87	-3.62	-3.07	-5.42	7.88	-5.89
Purchase of Property, Plant & Equipment	-0.40	-0.62	-0.56	-0.73	0.83	-2.88	-3.07	-4.38	7.88	-5.89
Net Cash From Financing Activities	-2.99	-0.42	-1.19	5.69	-3.91	-4.28	2.98	2.95	-15	2.21
Net Cash From Continuing Financing Activities	-2.99	-0.42	-1.19	5.69	-3.91	-4.28	2.98	2.95	-15	2.21
Repayment of Debt	-5.30	-3.18	-2.24	-5.95	-6.70	-3.91	-7.80	-3.15	-3.31	-1.00
Payment of Dividends	-2.78	-1.80	-1.38	-0.48	-0.88	-1.65	-1.15	-1.54	-1.26	-2.14
Issuance of Debt	1.13	3.10	2.13	2.92	4.02	1.28	11	7.60	-9.28	5.26
Other Financing Activities, net	3.96	1.46	0.30	0.00	-0.35	-	0.62	0.03	-0.90	0.09

This table presents Nutex Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	655	398	432
Total Current Assets	292	91	98
Cash & Equivalents	44	22	34
Accounts Receivable	236	63	58
Inventories, net	2.85	3.39	3.53
Prepaid Expenses	10.00	2.68	1.87
Plant, Property, & Equipment, net	78	81	82
Total Noncurrent Assets	285	226	252
Goodwill	14	17	17
Intangible Assets	16	21	21
Noncurrent Deferred & Refundable Income Taxes	7.99	0.00	-
Other Noncurrent Operating Assets	247	188	213
Total Liabilities & Shareholders' Equity	655	398	432
Total Liabilities	453	319	311
Total Current Liabilities	141	58	55
Short-Term Debt	18	14	15
Accounts Payable	9.61	25	28
Accrued Expenses	25	13	6.24
Current Deferred & Payable Income Tax Liabilities	26	0.00	-
Other Current Liabilities	62	5.90	5.92
Total Noncurrent Liabilities	313	261	257
Long-Term Debt	22	26	23
Capital Lease Obligations	259	214	204
Noncurrent Deferred & Payable Income Tax Liabilities	0.00	5.15	10
Other Noncurrent Operating Liabilities	31	15	19
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	202	79	120
Total Preferred & Common Equity	146	61	96
Total Common Equity	146	61	96
Common Stock	503	471	459
Retained Earnings	-357	-409	-363
Noncontrolling Interest	56	18	24

This table presents Nutex Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	438	422	404	480	436	430	435
Total Current Assets	120	114	100	90	92	89	108
Cash & Equivalents	47	41	30	27	33	33	37
Accounts Receivable	66	65	66	55	52	52	63
Inventories, net	2.26	2.76	2.98	2.68	2.45	3.49	3.21
Prepaid Expenses	4.28	5.07	1.63	5.65	4.86	0.83	4.38
Plant, Property, & Equipment, net	78	79	81	85	83	77	72
Total Noncurrent Assets	240	230	223	304	261	264	255
Goodwill	14	14	17	18	17	17	17
Intangible Assets	16	16	20	22	20	21	22
Other Noncurrent Operating Assets	211	200	186	265	224	226	216
Total Liabilities & Shareholders' Equity	438	422	404	480	436	430	435
Total Liabilities	359	340	324	375	328	321	302
Total Current Liabilities	68	72	60	67	57	48	44
Short-Term Debt	14	17	12	23	19	13	6.62
Accounts Payable	17	24	24	24	20	19	21
Accrued Expenses	30	23	18	15	12	10	10
Other Current Liabilities	7.32	7.57	5.95	5.73	5.66	5.61	5.59
Total Noncurrent Liabilities	291	269	264	307	271	273	258
Long-Term Debt	27	22	26	19	25	25	25
Capital Lease Obligations	241	227	213	264	-	221	205
Noncurrent Deferred & Payable Income Tax Liabilities	3.40	2.80	5.05	8.49	8.73	9.54	8.83
Other Noncurrent Operating Liabilities	20	17	20	16	237	17	20
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	80	82	80	105	108	110	133
Total Preferred & Common Equity	60	63	63	90	93	93	110
Total Common Equity	60	63	63	90	93	93	110
Common Stock	479	473	472	467	465	461	469
Retained Earnings	-419	-410	-409	-377	-372	-368	-359
Noncontrolling Interest	19	19	17	15	16	17	22

This table displays calculated financial ratios and metrics derived from Nutex Health's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	93.80%	12.93%	-33.85%
EBITDA Growth	1,119.47%	96.30%	-314.90%
EBIT Growth	503.07%	92.10%	-331.75%
NOPAT Growth	609.81%	92.19%	-268.12%
Net Income Growth	319.40%	89.97%	-356.78%
EPS Growth	193.46%	89.97%	-356.78%
Operating Cash Flow Growth	1,742.79%	-97.52%	-70.82%
Free Cash Flow Firm Growth	-473.21%	98.08%	-113.39%
Invested Capital Growth	47.10%	-5.01%	5.69%
Revenue Q/Q Growth	64.37%	6.88%	-30.23%
EBITDA Q/Q Growth	1,769.47%	-424.77%	-24.08%
EBIT Q/Q Growth	1,344.22%	-175.20%	-23.68%
NOPAT Q/Q Growth	1,764.22%	-178.53%	-23.78%
Net Income Q/Q Growth	393.97%	-64.67%	-22.50%
EPS Q/Q Growth	228.27%	-64.67%	-22.50%
Operating Cash Flow Q/Q Growth	8.58%	-83.33%	-45.30%
Free Cash Flow Firm Q/Q Growth	-152.99%	90.37%	38.40%
Invested Capital Q/Q Growth	45.70%	-18.92%	-1.17%
Profitability Metrics	-	-	-
Gross Margin	40.89%	14.04%	7.03%
EBITDA Margin	30.97%	-5.89%	-179.68%
Operating Margin	27.22%	-12.83%	-185.41%
EBIT Margin	27.02%	-12.99%	-185.67%
Profit (Net Income) Margin	19.85%	-17.53%	-197.33%
Tax Burden Percent	86.81%	89.55%	103.12%
Interest Burden Percent	84.63%	150.72%	103.07%
Effective Tax Rate	13.19%	0.00%	0.00%
Return on Invested Capital (ROIC)	29.46%	-6.96%	-89.20%
ROIC Less NNEP Spread (ROIC-NNEP)	22.05%	-16.59%	-180.00%
Return on Net Nonoperating Assets (RNNOA)	38.35%	-36.59%	-188.28%
Return on Equity (ROE)	67.81%	-43.55%	-277.48%
Cash Return on Invested Capital (CROIC)	-8.66%	-1.82%	-94.73%
Operating Return on Assets (OROA)	24.62%	-7.75%	-98.54%
Return on Assets (ROA)	18.09%	-10.46%	-104.73%
Return on Common Equity (ROCE)	50.15%	-34.35%	-187.28%
Return on Equity Simple (ROE_SIMPLE)	65.10%	-70.66%	-451.42%
Net Operating Profit after Tax (NOPAT)	113	-22	-285
NOPAT Margin	23.63%	-8.98%	-129.79%
Net Nonoperating Expense Percent (NNEP)	7.42%	9.63%	90.80%
Return On Investment Capital (ROIC_SIMPLE)	22.60%	-6.67%	-78.59%
Cost of Revenue to Revenue	27.67%	49.48%	56.50%
SG&A Expenses to Revenue	36.22%	42.80%	39.51%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	45.11%	63.35%	228.91%
Earnings before Interest and Taxes (EBIT)	130	-32	-407
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	149	-15	-394
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.18	1.96	12.88
Price to Tangible Book Value (P/TBV)	1.47	5.06	21.41
Price to Revenue (P/Rev)	0.36	0.49	5.63
Price to Earnings (P/E)	3.30	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	30.28%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.06	1.19	4.47
Enterprise Value to Revenue (EV/Rev)	1.01	1.50	6.69
Enterprise Value to EBITDA (EV/EBITDA)	3.26	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	3.73	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	4.27	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	20.91	295.10	28.98
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	1.49	3.22	2.01
Long-Term Debt to Equity	1.40	3.04	1.88
Financial Leverage	1.74	2.21	1.05
Leverage Ratio	3.75	4.16	2.65
Compound Leverage Factor	3.17	6.27	2.73
Debt to Total Capital	59.77%	76.28%	66.78%
Short-Term Debt to Total Capital	3.58%	4.25%	4.19%
Long-Term Debt to Total Capital	56.19%	72.03%	62.59%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	11.07%	5.29%	6.76%
Common Equity to Total Capital	29.16%	18.43%	26.47%
Debt to EBITDA	2.02	-17.45	-0.61
Net Debt to EBITDA	1.72	-15.94	-0.53
Long-Term Debt to EBITDA	1.90	-16.47	-0.58
Debt to NOPAT	2.64	-11.44	-0.85
Net Debt to NOPAT	2.26	-10.45	-0.73
Long-Term Debt to NOPAT	2.49	-10.80	-0.80
Altman Z-Score	1.13	-0.76	-1.28
Noncontrolling Interest Sharing Ratio	26.05%	21.12%	32.51%
Liquidity Ratios	-	-	-
Current Ratio	2.08	1.56	1.79
Quick Ratio	1.99	1.45	1.69
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-33	-5.81	-302
Operating Cash Flow to CapEx	1,004.98%	13.23%	345.86%
Free Cash Flow to Firm to Interest Expense	-1.67	-0.36	-24.20
Operating Cash Flow to Interest Expense	1.16	0.08	4.05
Operating Cash Flow Less CapEx to Interest Expense	1.05	-0.51	2.88
Efficiency Ratios	-	-	-
Asset Turnover	0.91	0.60	0.53
Accounts Receivable Turnover	3.21	4.09	2.53
Inventory Turnover	42.57	35.39	39.04
Fixed Asset Turnover	6.02	3.03	1.87
Accounts Payable Turnover	7.61	4.64	5.48
Days Sales Outstanding (DSO)	113.63	89.24	144.04
Days Inventory Outstanding (DIO)	8.58	10.31	9.35
Days Payable Outstanding (DPO)	47.95	78.66	66.55
Cash Conversion Cycle (CCC)	74.25	20.89	86.83
Capital & Investment Metrics	-	-	-
Invested Capital	458	311	328
Invested Capital Turnover	1.25	0.77	0.69
Increase / (Decrease) in Invested Capital	147	-16	18
Enterprise Value (EV)	484	371	1,467
Market Capitalization	172	121	1,235
Book Value per Share	$26.92	$0.09	$0.15
Tangible Book Value per Share	$21.50	$0.04	$0.09
Total Capital	502	333	362
Total Debt	300	254	242
Total Long-Term Debt	282	240	227
Net Debt	256	232	208
Capital Expenditures (CapEx)	2.30	9.50	15
Debt-free, Cash-free Net Working Capital (DFCFNWC)	126	25	24
Debt-free Net Working Capital (DFNWC)	170	47	58
Net Working Capital (NWC)	152	33	43
Net Nonoperating Expense (NNE)	18	21	148
Net Nonoperating Obligations (NNO)	256	232	208
Total Depreciation and Amortization (D&A)	19	18	13
Debt-free, Cash-free Net Working Capital to Revenue	26.25%	9.98%	10.96%
Debt-free Net Working Capital to Revenue	35.33%	18.86%	26.58%
Net Working Capital to Revenue	31.59%	13.14%	19.66%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$10.25	($10.50)	($100.50)
Adjusted Weighted Average Basic Shares Outstanding	5.53M	4.97M	4.34M
Adjusted Diluted Earnings per Share	$9.71	($10.50)	($100.50)
Adjusted Weighted Average Diluted Shares Outstanding	5.53M	4.97M	4.34M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	5.53M	4.97M	4.34M
Normalized Net Operating Profit after Tax (NOPAT)	120	-1.06	-3.20
Normalized NOPAT Margin	24.91%	-0.43%	-1.46%
Pre Tax Income Margin	22.87%	-19.58%	-191.36%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	6.51	-1.97	-32.60
NOPAT to Interest Expense	5.69	-1.36	-22.79
EBIT Less CapEx to Interest Expense	6.39	-2.55	-33.77
NOPAT Less CapEx to Interest Expense	5.57	-1.95	-23.96
Payout Ratios	-	-	-
Dividend Payout Ratio	6.76%	-12.01%	-11.84%
Augmented Payout Ratio	6.76%	-12.01%	-11.84%

This table displays calculated financial ratios and metrics derived from Nutex Health's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	269.77%	25.62%	29.12%	19.75%	29.68%	120.89%	1.51%	-28.81%	-63.88%	-75.93%
EBITDA Growth	645.70%	95.40%	243.28%	1,325.01%	-701.28%	100.94%	24.48%	-102.37%	-103.69%	-642.68%
EBIT Growth	529.22%	464.65%	3,848.23%	191.45%	-341.86%	99.82%	-1,065.89%	-117.47%	-108.33%	-661.69%
NOPAT Growth	674.57%	1,276.62%	1,709.99%	132.61%	-352.42%	99.81%	73.70%	-110.72%	-105.59%	-505.44%
Net Income Growth	460.75%	-58.38%	170.56%	92.16%	-159.99%	98.93%	82.22%	-127.88%	-115.48%	-667.71%
EPS Growth	28,000.00%	-37.60%	170.56%	92.16%	-159.99%	98.93%	82.22%	-127.88%	-115.48%	-788.89%
Operating Cash Flow Growth	103.01%	244.93%	107,538.69%	190.00%	-139.42%	126.96%	-99.93%	-97.06%	-90.29%	-130.11%
Free Cash Flow Firm Growth	-2,117.77%	244.41%	-129.71%	113.10%	91.37%	90.56%	191.75%	-1,036.19%	90.90%	-18,760.86%
Invested Capital Growth	47.10%	-18.14%	156.37%	-10.40%	-5.01%	15.79%	-83.74%	419.67%	5.69%	367.29%
Revenue Q/Q Growth	226.95%	3.57%	12.79%	-3.18%	11.07%	6.45%	4.61%	4.85%	89.20%	-51.08%
EBITDA Q/Q Growth	1,429.78%	-42.39%	59.14%	138.91%	-647.79%	1.22%	667.89%	74.55%	99.36%	-13,520.63%
EBIT Q/Q Growth	3,957.42%	-68.74%	108.75%	116.21%	-3,346.96%	-221.33%	94.91%	21.68%	98.60%	-1,729,945.58%
NOPAT Q/Q Growth	1,454.63%	65.55%	302.65%	105.54%	-3,083.64%	-126.52%	91.84%	23.08%	98.65%	-30,998.14%
Net Income Q/Q Growth	1,495.24%	-338.02%	654.89%	98.04%	-512.55%	-6.04%	38.36%	35.06%	97.48%	-1,662.26%
EPS Q/Q Growth	748.84%	-2,357.14%	654.89%	98.04%	-512.55%	-6.04%	38.36%	35.06%	97.48%	-1,966.67%
Operating Cash Flow Q/Q Growth	-99.21%	-48.80%	334.63%	271.76%	-190.24%	15,878.07%	-98.83%	-76.65%	161.71%	-141.34%
Free Cash Flow Firm Q/Q Growth	-154.35%	141.67%	-609.74%	2,020.92%	96.46%	-108.57%	324.86%	-1,165.63%	96.13%	16.69%
Invested Capital Q/Q Growth	45.70%	2.24%	2.07%	-3.26%	-18.92%	220.23%	-64.33%	2.57%	-1.17%	-55.04%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	54.98%	27.82%	29.65%	15.06%	18.97%	11.27%	16.37%	8.61%	-6.18%	-83.51%
EBITDA Margin	46.16%	9.86%	17.73%	12.57%	-31.28%	6.34%	6.67%	-1.23%	-5.06%	-1,492.23%
Operating Margin	44.33%	12.26%	6.96%	2.15%	-37.53%	-1.31%	-0.62%	-7.89%	-10.76%	-1,509.70%
EBIT Margin	44.11%	3.55%	11.78%	6.36%	-38.00%	-1.22%	-0.41%	-8.33%	-11.15%	-1,507.48%
Profit (Net Income) Margin	38.81%	-9.09%	3.96%	-0.80%	-39.78%	-7.21%	-7.24%	-12.29%	-19.84%	-1,489.38%
Tax Burden Percent	92.07%	277.66%	77.10%	354.98%	90.24%	92.97%	83.95%	88.37%	120.39%	98.02%
Interest Burden Percent	95.55%	-92.14%	43.58%	-3.56%	116.00%	633.60%	2,126.30%	166.92%	147.77%	100.79%
Effective Tax Rate	7.93%	0.00%	22.90%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	50.90%	7.18%	6.93%	1.22%	-20.35%	-0.59%	-0.20%	-5.41%	-5.17%	-1,649.15%
ROIC Less NNEP Spread (ROIC-NNEP)	48.78%	1.76%	6.03%	0.53%	-24.63%	-2.24%	-4.58%	-8.90%	-9.23%	-1,774.26%
Return on Net Nonoperating Assets (RNNOA)	84.84%	4.89%	7.52%	1.24%	-54.33%	-4.52%	-1.24%	-10.64%	-9.65%	-1,687.30%
Return on Equity (ROE)	135.74%	12.06%	14.45%	2.46%	-74.68%	-5.12%	-1.44%	-16.06%	-14.83%	-3,336.44%
Cash Return on Invested Capital (CROIC)	-8.66%	18.00%	-94.38%	5.29%	-1.82%	-16.86%	72.38%	-289.14%	-94.73%	-243.65%
Operating Return on Assets (OROA)	40.19%	2.26%	7.57%	3.95%	-22.68%	-0.62%	-0.12%	-6.38%	-5.92%	-1,830.10%
Return on Assets (ROA)	35.36%	-5.78%	2.54%	-0.50%	-23.74%	-3.66%	-2.19%	-9.41%	-10.53%	-1,808.12%
Return on Common Equity (ROCE)	100.38%	9.82%	11.80%	2.02%	-58.91%	-4.32%	-1.32%	-14.47%	-10.01%	-2,980.04%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-53.62%	-47.45%	-58.78%	0.00%	-29.32%	-480.20%	-501.52%	0.00%	-319.72%
Net Operating Profit after Tax (NOPAT)	105	6.76	4.09	1.01	-18	-0.57	-0.25	-3.11	-4.05	-300
NOPAT Margin	40.82%	8.58%	5.37%	1.50%	-26.27%	-0.92%	-0.43%	-5.52%	-7.53%	-1,056.79%
Net Nonoperating Expense Percent (NNEP)	2.12%	5.42%	0.91%	0.70%	4.28%	1.65%	4.38%	3.49%	4.05%	125.12%
Return On Investment Capital (ROIC_SIMPLE)	20.96%	-	-	-	-5.49%	-	-	-	-1.12%	-
Cost of Revenue to Revenue	13.46%	42.94%	42.04%	47.92%	46.23%	51.55%	47.73%	53.01%	113.86%	111.06%
SG&A Expenses to Revenue	34.47%	35.46%	36.35%	43.65%	40.28%	42.05%	45.39%	44.03%	38.37%	80.98%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	42.21%	44.80%	50.99%	49.93%	91.29%	49.76%	52.88%	54.88%	-3.11%	1,498.65%
Earnings before Interest and Taxes (EBIT)	114	2.80	8.96	4.29	-26	-0.77	-0.24	-4.69	-5.99	-428
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	119	7.77	13	8.48	-22	3.98	3.93	-0.69	-2.72	-424
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.18	1.82	0.47	1.13	1.96	1.49	2.99	7.10	12.88	8.82
Price to Tangible Book Value (P/TBV)	1.47	3.58	0.91	2.77	5.06	2.66	5.02	12.00	21.41	13.56
Price to Revenue (P/Rev)	0.36	0.38	0.11	0.28	0.49	0.58	1.40	3.35	5.63	3.10
Price to Earnings (P/E)	3.30	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	30.28%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.06	1.16	0.89	1.03	1.19	1.11	2.54	2.68	4.47	3.60
Enterprise Value to Revenue (EV/Rev)	1.01	1.25	0.99	1.20	1.50	1.85	1.54	4.59	6.69	3.81
Enterprise Value to EBITDA (EV/EBITDA)	3.26	45.77	66.02	0.00	0.00	95.39	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	3.73	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	4.27	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	20.91	17.07	16.63	95.17	295.10	56.81	0.00	56.61	28.98	12.93
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	5.79	0.00	18.36	0.00	0.00	0.98	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.49	3.53	3.25	3.14	3.22	2.92	0.41	2.37	2.01	1.78
Long-Term Debt to Equity	1.40	3.36	3.04	2.99	3.04	2.70	0.23	2.25	1.88	1.73
Financial Leverage	1.74	2.78	1.25	2.36	2.21	2.02	0.27	1.20	1.05	0.95
Leverage Ratio	3.75	4.97	4.51	4.40	4.16	3.85	1.94	2.81	2.65	2.51
Compound Leverage Factor	3.58	-4.58	1.97	-0.16	4.83	24.39	41.23	4.69	3.92	2.53
Debt to Total Capital	59.77%	77.92%	76.46%	75.85%	76.28%	74.48%	29.14%	70.33%	66.78%	64.03%
Short-Term Debt to Total Capital	3.58%	3.84%	4.92%	3.67%	4.25%	5.60%	12.70%	3.56%	4.19%	1.80%
Long-Term Debt to Total Capital	56.19%	74.08%	71.54%	72.18%	72.03%	68.88%	16.44%	66.77%	62.59%	62.23%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	11.07%	5.35%	5.54%	5.13%	5.29%	3.64%	10.22%	4.58%	6.76%	5.98%
Common Equity to Total Capital	29.16%	16.72%	18.01%	19.02%	18.43%	21.88%	60.64%	25.09%	26.47%	29.99%
Debt to EBITDA	2.02	35.42	64.08	-46.50	-17.45	68.18	-0.11	-0.61	-0.61	-0.74
Net Debt to EBITDA	1.72	29.52	54.27	-40.95	-15.94	62.20	-0.03	-0.53	-0.53	-0.63
Long-Term Debt to EBITDA	1.90	33.67	59.96	-44.25	-16.47	63.05	-0.06	-0.58	-0.58	-0.72
Debt to NOPAT	2.64	-41.33	-18.82	-13.87	-11.44	-38.33	-0.14	-0.84	-0.85	-1.03
Net Debt to NOPAT	2.26	-34.45	-15.94	-12.22	-10.45	-34.97	-0.04	-0.74	-0.73	-0.87
Long-Term Debt to NOPAT	2.49	-39.29	-17.61	-13.20	-10.80	-35.45	-0.08	-0.80	-0.80	-1.00
Altman Z-Score	1.05	-0.32	-0.46	-0.49	-0.71	-0.35	-0.14	0.57	1.78	-1.57
Noncontrolling Interest Sharing Ratio	26.05%	18.58%	18.34%	17.89%	21.12%	15.59%	8.35%	9.91%	32.51%	10.68%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.08	1.77	1.59	1.68	1.56	1.34	1.60	1.85	1.79	2.45
Quick Ratio	1.99	1.68	1.48	1.60	1.45	1.21	1.48	1.76	1.69	2.28
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-42	76	-184	36	-1.87	-53	618	-275	-22	-561
Operating Cash Flow to CapEx	13.53%	1,100.12%	2,375.63%	416.03%	0.00%	68.45%	0.40%	24.04%	0.00%	-123.96%
Free Cash Flow to Firm to Interest Expense	-8.23	14.21	-36.31	8.10	-0.44	-12.92	127.55	-87.49	-7.58	-164.84
Operating Cash Flow to Interest Expense	0.01	1.26	2.62	0.69	-0.42	0.48	0.00	0.34	1.57	-2.15
Operating Cash Flow Less CapEx to Interest Expense	-0.07	1.15	2.51	0.52	-0.22	-0.22	-0.63	-1.06	4.33	-3.88
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.91	0.64	0.64	0.62	0.60	0.51	0.30	0.77	0.53	1.21
Accounts Receivable Turnover	3.21	4.82	4.71	4.41	4.09	3.93	2.67	7.33	2.53	9.86
Inventory Turnover	42.57	52.75	49.46	38.69	35.39	51.39	56.25	0.00	39.04	0.00
Fixed Asset Turnover	6.02	3.57	3.41	3.28	3.03	2.94	2.62	5.10	1.87	8.70
Accounts Payable Turnover	7.61	6.45	5.87	5.81	4.64	6.72	6.86	13.12	5.48	12.87
Days Sales Outstanding (DSO)	113.63	75.65	77.55	82.70	89.24	92.96	136.90	49.82	144.04	37.02
Days Inventory Outstanding (DIO)	8.58	6.92	7.38	9.43	10.31	7.10	6.49	0.00	9.35	0.00
Days Payable Outstanding (DPO)	47.95	56.57	62.15	62.85	78.66	54.33	53.18	27.81	66.55	28.37
Cash Conversion Cycle (CCC)	74.25	26.00	22.78	29.28	20.89	45.73	90.21	22.01	86.83	8.66
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	458	314	308	301	311	384	120	336	328	332
Invested Capital Turnover	1.25	0.84	1.29	0.81	0.77	0.65	0.46	0.98	0.69	1.56
Increase / (Decrease) in Invested Capital	147	-70	188	-35	-16	52	-618	272	18	261
Enterprise Value (EV)	484	364	274	310	371	428	304	901	1,467	1,196
Market Capitalization	172	110	30	71	121	134	277	657	1,235	975
Book Value per Share	$26.92	$11.93	$1.26	$0.08	$0.09	$0.14	$0.14	$0.14	$0.15	$0.17
Tangible Book Value per Share	$21.50	$6.05	$0.66	$0.03	$0.04	$0.08	$0.08	$0.08	$0.09	$0.11
Total Capital	502	361	348	331	333	411	153	369	362	368
Total Debt	300	282	266	251	254	306	44	260	242	236
Total Long-Term Debt	282	268	249	239	240	283	25	247	227	229
Net Debt	256	235	226	221	232	279	12	227	208	199
Capital Expenditures (CapEx)	0.40	0.62	0.56	0.73	-0.83	2.88	3.07	4.38	-7.88	5.89
Debt-free, Cash-free Net Working Capital (DFCFNWC)	126	19	19	23	25	19	21	21	24	34
Debt-free Net Working Capital (DFNWC)	170	66	59	53	47	46	54	54	58	70
Net Working Capital (NWC)	152	52	42	40	33	23	35	41	43	64
Net Nonoperating Expense (NNE)	5.18	14	1.08	1.56	9.41	3.95	4.01	3.81	6.61	123
Net Nonoperating Obligations (NNO)	256	235	226	221	232	279	12	227	208	199
Total Depreciation and Amortization (D&A)	5.28	4.97	4.53	4.19	4.68	4.75	4.17	4.00	3.27	4.33
Debt-free, Cash-free Net Working Capital to Revenue	26.25%	6.58%	6.72%	8.74%	9.98%	8.10%	10.78%	10.73%	10.96%	10.73%
Debt-free Net Working Capital to Revenue	35.33%	22.64%	21.51%	20.34%	18.86%	19.68%	27.37%	27.44%	26.58%	22.38%
Net Working Capital to Revenue	31.59%	17.89%	15.30%	15.64%	13.14%	9.75%	17.55%	20.76%	19.66%	20.27%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$11.16	($1.72)	($0.07)	($0.10)	($6.00)	($1.50)	($1.50)	($1.50)	($3.00)	($97.50)
Adjusted Weighted Average Basic Shares Outstanding	5.53M	5.44M	5.07M	4.97M	4.97M	4.47M	4.41M	4.38M	4.34M	4.33M
Adjusted Diluted Earnings per Share	$11.16	($1.72)	($0.07)	($0.10)	($6.00)	($1.50)	($1.50)	($1.50)	($3.00)	($97.50)
Adjusted Weighted Average Diluted Shares Outstanding	5.53M	5.44M	5.07M	4.97M	4.97M	4.47M	4.41M	4.38M	4.34M	4.33M
Adjusted Basic & Diluted Earnings per Share	$11.16	$0.00	$0.00	$0.00	($6.00)	$0.00	$0.00	$0.00	($3.00)	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	5.53M	5.44M	5.07M	4.97M	4.97M	4.47M	4.41M	4.38M	4.34M	4.33M
Normalized Net Operating Profit after Tax (NOPAT)	105	7.06	9.23	1.01	-18	-0.54	-0.25	-3.11	-4.05	-21
Normalized NOPAT Margin	40.82%	8.96%	12.13%	1.50%	-26.27%	-0.87%	-0.43%	-5.52%	-7.53%	-75.30%
Pre Tax Income Margin	42.15%	-3.27%	5.13%	-0.23%	-44.08%	-7.76%	-8.62%	-13.91%	-16.48%	-1,519.46%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	22.49	0.52	1.77	0.97	-6.25	-0.19	-0.05	-1.49	-2.09	-125.80
NOPAT to Interest Expense	20.81	1.26	0.81	0.23	-4.32	-0.14	-0.05	-0.99	-1.41	-88.19
EBIT Less CapEx to Interest Expense	22.41	0.41	1.66	0.80	-6.05	-0.89	-0.68	-2.89	0.66	-127.53
NOPAT Less CapEx to Interest Expense	20.74	1.14	0.70	0.06	-4.13	-0.84	-0.69	-2.38	1.34	-89.92
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	6.76%	-14.00%	-14.75%	-11.23%	-12.01%	-21.21%	-1.37%	-4.29%	-11.84%	-26.22%
Augmented Payout Ratio	6.76%	-14.00%	-14.75%	-11.23%	-12.01%	-21.21%	-1.37%	-4.29%	-11.84%	-26.22%

Frequently Asked Questions About Nutex Health's Financials

When does Nutex Health's financial year end?

According to the most recent income statement we have on file, Nutex Health's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Nutex Health's net income changed over the last 2 years?

Nutex Health's net income appears to be on a downward trend, with a most recent value of $95.27 million in 2024, falling from -$432.74 million in 2022. The previous period was -$43.42 million in 2023. Check out Nutex Health's forecast to explore projected trends and price targets.

What is Nutex Health's operating income?

Nutex Health's total operating income in 2024 was $130.62 million, based on the following breakdown:

Total Gross Profit: $196.26 million
Total Operating Expenses: $216.52 million

How has Nutex Health revenue changed over the last 2 years?

Over the last 2 years, Nutex Health's total revenue changed from $219.29 million in 2022 to $479.95 million in 2024, a change of 118.9%.

How much debt does Nutex Health have?

Nutex Health's total liabilities were at $453.43 million at the end of 2024, a 42.1% increase from 2023, and a 45.6% increase since 2022.

How much cash does Nutex Health have?

In the past 2 years, Nutex Health's cash and equivalents has ranged from $22.00 million in 2023 to $43.58 million in 2024, and is currently $43.58 million as of their latest financial filing in 2024.

How has Nutex Health's book value per share changed over the last 2 years?

Over the last 2 years, Nutex Health's book value per share changed from 0.15 in 2022 to 26.92 in 2024, a change of 18,148.4%.

Related Companies

This page (NASDAQ:NUTX) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nutex Health (NUTX) Financials

Frequently Asked Questions About Nutex Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nutex Health (NUTX) Financials

Annual Income Statements for Nutex Health

Quarterly Income Statements for Nutex Health

Annual Cash Flow Statements for Nutex Health

Quarterly Cash Flow Statements for Nutex Health

Annual Balance Sheets for Nutex Health

Quarterly Balance Sheets for Nutex Health

Annual Metrics And Ratios for Nutex Health

Quarterly Metrics And Ratios for Nutex Health

Frequently Asked Questions About Nutex Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools